Xencor (XNCR) Common Equity (2013 - 2026)
Xencor (XNCR) reported Common Equity of $515.6 million for Q1 2026, down 19.42% year-over-year from $639.9 million in Q1 2025, and down 18.87% quarter-over-quarter from $635.6 million in Q4 2025.
Xencor (XNCR) Common Equity (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Common Equity data on file, last reported at $515.6 million in Q1 2026.
- Common Equity for Q1 2026 came in at $515.6 million, down 19.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $515.6 million (down 19.42% YoY), and the FY2025 annual result was $635.6 million, down 5.7% from the prior year.
- Common Equity slipped to $515.6 million in Q1 2026 per XNCR's latest filing, from $635.6 million in the prior quarter.
- Over five years, Common Equity peaked at $763.0 million in Q1 2022 and troughed at $515.6 million in Q1 2026.
- A 5-year average of $659.7 million and a median of $669.0 million in 2023 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2026: Common Equity surged 30.74% in 2022, then decreased 19.42% in 2026.
- A 5-year view of Common Equity shows it stood at $727.5 million in 2022, then fell by 8.99% to $662.1 million in 2023, then increased by 1.8% to $674.0 million in 2024, then declined by 5.7% to $635.6 million in 2025, then decreased by 18.87% to $515.6 million in 2026.
- Business Quant data shows XNCR's Common Equity at $515.6 million in Q1 2026, $635.6 million in Q4 2025, and $625.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 35.63 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.42 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 13.21 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 14.38 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 11.87 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.36 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | 515.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 515.63 Mn |
| Dec 31, 2025 | 635.59 Mn |
| Sep 30, 2025 | 625.32 Mn |
| Jun 30, 2025 | 620.35 Mn |
| Mar 31, 2025 | 639.87 Mn |
| Dec 31, 2024 | 674.03 Mn |
| Sep 30, 2024 | 705.93 Mn |
| Jun 30, 2024 | 548.71 Mn |
| Mar 31, 2024 | 599.73 Mn |
| Dec 31, 2023 | 662.09 Mn |
| Sep 30, 2023 | 669.01 Mn |
| Jun 30, 2023 | 678.88 Mn |
| Mar 31, 2023 | 683.58 Mn |
| Dec 31, 2022 | 727.50 Mn |
| Sep 30, 2022 | 722.70 Mn |
| Jun 30, 2022 | 742.34 Mn |
| Mar 31, 2022 | 763.02 Mn |
| Dec 31, 2021 | 733.50 Mn |
| Sep 30, 2021 | 618.86 Mn |
| Jun 30, 2021 | 646.94 Mn |